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Abstract 
Short communication on PHLDA1, with data on 
DNA/RNA, on the protein encoded and where the 
gene is implicated. 
Identity 
Other names: DT1P1B11, PHRIP, TDAG51 
HGNC (Hugo): PHLDA1 
Location: 12q21.2 
Local order: Minus strand. 
DNA/RNA 
Description 
PHLDA1 gene contains 2 exons, 1 intervening 
sequence and spans 6,3 kb of genomic DNA. 
Transcription 
1,2 kb mRNA. 
Pseudogene 
Not identified. 
Protein 
Description 
The PHLDA1 gene encodes for a 401 amino acid 
protein that is a member of the evolutionarily 
conserved pleckstrin homology-like domain family.  
PHLDA1 protein has a modular structure 
containing a central pleckstrin homology-like 
domain (PHL) and prolin-glutamine (PQ) and 
proline-histidine (PH) repeats in the C-terminal 
region (see figure above). 
Expression 
PHLDA1 is widely expressed in mammalian tissues 
displaying cytoplasmic, vesicle membrane, plasma 
membrane and nuclear subcellular localization. 
PHLDA1 expression is up-regulated by estrogen, 
IGF-1 (insulin-like growth factor 1), FGF 
(fibroblast growth factor), TPA (phorbol ester), and 
ER (endoplamic reticulum)-stress agents such as 
homocysteine, tunicamicyne, and farnesol. 
Localisation 
Cytoplasm, vesicle membrane, plasma membrane, 
nucleus. 
Function 
Protein binding. Several evidences have implicate 
PHLDA1 as a potential transcriptional activator that 
acts as a pro-apoptotic and antiproliferative factor, 
however the mechanisms by which PHLDA1 
mediates cell survival is still under investigation. 
Homology 
PHLDA2 (pleckstrin homology-like domain, family 
A, member 2) and PHLDA3 (pleckstrin homology-
like domain, family A, member 3) are paralogs for 
PHLDA1. 
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Schematic representation of the modular structure of PHLDA1 protein. PHL: pleckstrin homology-like domain spanning 
amino acids residues from 150 to 283; QQ: proline/glutamine rich sequence (aa residues from 189 to 204); PQ: proline-
glutamine tracts (aa residues from 311 to 346); PH: proline-histidine-rich tracts (aa residues from 352 to 389); *: indicates 
phosphorylation sites. 
 
Mutations 
Note 
Short genetic variation - dbSNP: rs139162669, 
rs73385441, rs74620794, rs147230079, 
rs76437300, rs186978611, rs140610935, 
rs144470255, rs79545253, rs147644129. 
Implicated in 
Melanoma 
Note 
PHLDA1 expression was associated with reduced 
cell growth and colony formation and with 
increased apoptotic rates and drug sensitivity in 
melanoma cell lines. Loss of PHLDA1 has been 
correlated with melanoma progression (Neef et al., 
2002). 
Breast cancer 
Note 
Down-regulation of PHLDA1 mRNA and protein 
expression is frequently observed in primary 
invasive breast tumours.  
Down-regulation of PHLDA1 protein has been 
shown to be a strong predictor of poor prognosis for 
breast cancer patients, indicating that reduced 
PHLDA1 expression contribute for breast cancer 
progression and might serve as useful prognostic 
biomarker of disease outcome (Nagai et al., 2007). 
Oral cancer 
Note 
Reduced expression of PHLDA1 was observed in 
60,7% of oral squamous cell carcinomas (OSCC), 
especially in well-differentiated tumors.  
Positive PHLDA1 immunostaining was associated 
with advanced clinical stages of the disease, 
suggesting that PHLDA1 has a functional role in 
oral tumorigenesis.  
Overall and disease-free survival rates were  
significantly better in patients with tumors that 
were negative for PHLDA1, and a multivariate 
analysis suggested that PHLDA1 is an independent 
prognostic factor in OSCC patients (Coutinho-
Camillo et al., 2013). 
Colon cancer 
Note 
Altered PHLDA1 expression has been shown to be 
associated with the process of intestinal 
tumorigenesis (Sakthianandeswaren et al., 2011). 
Basal cell carcinoma 
Note 
PHLDA1 has also been shown to be a follicular and 
epithelial stem cell marker (Ohyama et al., 2006; 
Sakthianandeswaren et al., 2011) with potential to 
differentiates between trichoepithelioma and basal 
cell carcinoma (Sellheyer and Nelson, 2011). 
Atherosclerosis 
Note 
In vivo and in vitro studies demonstrated that 
increased PHLDA1 expression induced by 
homocysteine promotes detachment-mediated 
programmed cell death and contributes to the 
development of atherosclerosis (Hossain et al., 
2003).  
Genetic variant in an intergenic region of the 
PHLDA1 gene (rs2367446) has been shown to be 
associated with the development of cardiovascular 
diseases (Hossain et al., 2013). 
Epilepsy 
Note 
PHLDA1 expression has been shown to be higher 
in the anterior temporal neocortex from patients 
with intractable epilepsy when compared with the 
levels observed in the neocortex from the control 
group, suggesting a possible association of 
PHLDA1 in the physiopathology of the disease (Xi 
et al., 2007). 
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